arimoclomol

Absorption: Extent of absorption following oral administration unknown.

Distribution: Widely distributed to tissues.

Metabolism/Excretion: Primarily metabolized in the liver via glutathionation and O-glucuronidation. 12% excreted in feces; 78% excreted in urine (42% as unchanged drug).

Half-Life: 4 hr.

Time/Action Profile ⬆ ⬇

(plasma concentrations)

ROUTE	ONSET	PEAK	DURATION
PO	unknown	0.5 hr	12 hr

Contraind./Precautions ⬆ ⬇

Contraindicated in:

OB: Pregnancy.

Use Cautiously in:

eGFR 15–<50 mL/min (adjust dosage frequency);
End-stage renal disease;
Rep: Women of reproductive potential;
Lactation: Safety not established in breastfeeding;
Pedi: Children <2 yr (safety and effectiveness not established).

Adv. Reactions/Side Effects ⬆ ⬇

Derm: urticaria

GI: diarrhea

GU: ↓fertility, ↑serum creatinine

Hemat: thrombocytopenia

Metab: ↓appetite, weight loss

Neuro: headache, seizure, tremor

Resp: respiratory tract infection

Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANGIOEDEMA)

Interactions ⬆ ⬇

Drug-drug:

May ↑ levels and risk of toxicity of organic cationic transporter 2 (OCT2) substrates; ↓ dose of OCT2 substrate.

Route/Dosage ⬆ ⬇

PO (Adults and Children ≥2 yr and >55 kg): 124 mg three times daily.
PO (Adults and Children ≥2 yr and >30–55 kg): 93 mg three times daily.
PO (Adults and Children ≥2 yr and >15–30 kg): 62 mg three times daily.
PO (Adults and Children ≥2 yr and 8–15 kg): 47 mg three times daily.

Renal Impairment

PO (Adults and Children ≥2 yr and >55 kg): CCr 15–<50 mL/min: 124 mg twice daily.

Renal Impairment

PO (Adults and Children ≥2 yr and >30–55 kg): CCr 15–<50 mL/min: 93 mg twice daily.

Renal Impairment

PO (Adults and Children ≥2 yr and >15–30 kg): CCr 15–<50 mL/min: 62 mg twice daily.

Renal Impairment

PO (Adults and Children ≥2 yr and 8–15 kg): CCr 15–<50 mL/min: 47 mg twice daily.

Availability ⬆ ⬇

Capsules: 47 mg; 62 mg; 93 mg; 124 mg

Assessment ⬆ ⬇

Monitor for hypersensitivity reactions (urticaria, angioedema, dyspnea, persistent cough, facial swelling). Implement immediate emergency measures (epinephrine) based on symptoms.
Assess baseline weight. Monitor for ↓ in weight and appetite during therapy.
Assess baseline cognitive function, coordination, muscle strength, and reflexes and monitor during treatment.

Lab Test Considerations:

Monitor for ↑ serum creatinine.
Monitor for thrombocytopenia.

Implementation ⬆ ⬇

PO: Administer with or without food. Swallow capsule whole.
If difficulty swallowing capsules, open capsule and sprinkle contents into 15 mL of water, apple juice, or soft food (applesauce, pudding, yogurt). Stir for 15 sec and consume entire mixture immediately.
Feeding tube (nasogastric or gastric tube): Open capsule and sprinkle contents into 20 mL of water. Do not use any other liquid. Stir for 15 sec and administer immediately via tube. Flush with 5 mL of water after administration. Do not save mixture for later use.

Patient/Family Teaching ⬆ ⬇

Explain purpose and side effects of medication. Advise patient to read Patient Information before starting therapy. If a dose is missed, skip the dose, and resume dosing at next scheduled time.
Advise patient to notify health care professional of all Rx or OTC medications, vitamins, or herbal products being taken and to consult health care professional before taking other medications.
Advise patient to notify health care professional of signs/symptoms of hypersensitivity reactions and seek immediate medical attention if needed.
Rep: Advise women of reproductive potential to notify health care professional if pregnancy is planned or suspected or if breastfeeding. Advise patient to use effective contraception during treatment. May impair fertility.

section name header

Pronunciation ⬇

Classifications ⬆ ⬇

Indications ⬆ ⬇

Action ⬆ ⬇

Pharmacokinetics ⬆ ⬇

Time/Action Profile ⬆ ⬇

Contraind./Precautions ⬆ ⬇

Adv. Reactions/Side Effects ⬆ ⬇

Interactions ⬆ ⬇

Route/Dosage ⬆ ⬇

Availability ⬆ ⬇

Assessment ⬆ ⬇

Implementation ⬆ ⬇

Patient/Family Teaching ⬆ ⬇

Evaluation/Desired Outcomes ⬆ ⬇

US Brand Names ⬆